Cargando…
Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation
The terminal pathway of complement is implicated in the pathology of multiple diseases and its inhibition is, therefore, an attractive therapeutic proposition. The practicalities of inhibiting this pathway, however, are challenging, as highlighted by the very few molecules in the clinic. The protein...
Autores principales: | Stach, Lasse, Dinley, Emily K. H., Tournier, Nadia, Bingham, Ryan P., Gormley, Darren A., Bramhall, Jo L., Taylor, Adam, Clarkson, Jane E., Welbeck, Katherine A., Harris, Claire L., Feeney, Maria, Hughes, Jane P., Sepp, Armin, Batuwangala, Thil D., Kitchen, Semra J., Nichols, Eva-Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544208/ https://www.ncbi.nlm.nih.gov/pubmed/34698051 http://dx.doi.org/10.3390/antib10040039 |
Ejemplares similares
-
The neoepitope of the complement C5b-9 Membrane Attack Complex is formed by proximity of adjacent ancillary regions of C9
por: Bayly-Jones, Charles, et al.
Publicado: (2023) -
The neoepitope landscape in pediatric cancers
por: Chang, Ti-Cheng, et al.
Publicado: (2017) -
Pan-cancer analysis of neoepitopes
por: Teku, Gabriel N., et al.
Publicado: (2018) -
Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
por: Lekova, Eleonora, et al.
Publicado: (2022) -
Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept
por: Walker, Adam, et al.
Publicado: (2016)